Corium International
Corium International (Corium, Inc.) is a U.S. CNS pharmaceutical company commercializing AZSTARYS, an FDA-approved ADHD medication, in the United States, with an Alzheimer's treatment in its development pipeline.
- Company typePublic
- Founded1995
- HeadquartersMenlo Park, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Corium International does
Corium International (legal entity Corium, Inc.) is a U.S.-based pharmaceutical company founded in 1995 and headquartered in Menlo Park, California, focused on central nervous system (CNS) therapeutics. The company historically developed transdermal drug delivery technologies and has concentrated its commercial efforts on AZSTARYS, an FDA-approved ADHD medication, with U.S. commercialization supported by a $235 million term loan facility from Hercules Capital executed in September 2021. Beyond AZSTARYS, Corium is advancing an Alzheimer's disease treatment through its development pipeline, representing its primary pipeline-stage asset.
Corium's product portfolio is anchored on a single approved CNS asset (AZSTARYS) and one pipeline-stage Alzheimer's program. The company executed a SPAC-led transition to public-market status around 2021 under the ticker CORI, and subsequently the security is listed as delisted. Earlier corporate history includes the 2007 acquisition of StrataGent Life Sciences to extend transdermal delivery capabilities, and a series of equity and debt financings between 2007 and 2021 totaling on the order of $448 million (aggregating the disclosed rounds). Leadership is anchored by founder Gary W. Cleary, who serves as President and CTO.
Revenue mechanics are tied to U.S. pharmaceutical product sales of AZSTARYS via direct/field-sales distribution to prescribers and downstream pharmacy channels. Corium has 501-1,000 employees per the firmographics, and the company pursued enterprise field sales as its go-to-market model. No public pricing for AZSTARYS or other terms is disclosed, and no revenue figure is available in the source data. Operating status indicators are mixed: financing through 2021 supports ongoing operations, but the corporate website (coriumgroup.com) currently returns a CloudAccess.net error page rather than active content, and the equity is delisted, suggesting significant operational or market-structure stress following the 2021 transition.
Corium International firmographics
Firmographics- Name
- Corium International
- Legal name
- Corium, Inc.
- Website
- https://coriumgroup.com
- Company type
- Public
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Corium International (Corium, Inc.) is a U.S. CNS pharmaceutical company commercializing AZSTARYS, an FDA-approved ADHD medication, in the United States, with an Alzheimer's treatment in its development pipeline.
- Ownership category
- akta.pro rank
Where Corium International is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Markets served
Corium International business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Marketing or Sales, Technology or R&D, Supply Chain, Personnel
Revenue model
- Pharmaceutical Product Sales: Revenue generated from commercialization of FDA-approved drugs, specifically AZSTARYS for ADHD treatment. The company is pursuing traditional pharmaceutical commercialization with initial U.S. focus.
Go-to-market motion1 record
Distribution channels1 record
Corium International product offering
Product offeringCore offering
Corium International is a pharmaceutical company that develops and commercializes advanced transdermal drug delivery technologies and CNS (central nervous system) therapies. Its primary commercial product is AZSTARYS, an FDA-approved medication for ADHD, while it also advances a development pipeline including an Alzheimer's disease treatment.
Product overview
Corium International is a pharmaceutical company focused on CNS (central nervous system) therapies. The company operates a portfolio that includes AZSTARYS, an FDA-approved ADHD drug that is being commercialized in the U.S. market, alongside a pipeline of CNS treatments including an Alzheimer's disease therapy in development. The product strategy centers on bringing novel CNS medications to market, with initial commercialization efforts concentrated on AZSTARYS.
Differentiator
Problem solved
Functional benefit
Brands
- AZSTARYS: FDA-approved ADHD medication commercialized by Corium.
Products and services
- AZSTARYS
- Alzheimer's Treatment (Pipeline)
Companies that use Corium International
Customer profileSegments2 records
Ideal customer profiles1 record
Corium International technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Corium International partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Corium International competitors and assessment
Company assessmentBroad incumbents
- Biogen: Major CNS-focused biotech with leading Alzheimer's programs (e.g., Aduhelm, Leqembi). Relevant comparator for the Alzheimer's development pathway Corium is pursuing.
- Jazz Pharmaceuticals: Larger specialty pharma with a significant CNS franchise including ADHD-adjacent products. Comparable as a CNS-focused commercial-stage specialty pharmaceutical operator, though broader and more diversified than Corium.
- Pfizer: Large incumbent pharma with a major ADHD portfolio (Quillivant, Quillichew) and significant CNS R&D. Overlaps with Corium in ADHD commercialization and CNS pipeline development.
- Teva Pharmaceutical Industries: Global generic and specialty pharma with a leading ADHD franchise (generic Adderall, branded equivalents). Competes directly with AZSTARYS in the U.S. ADHD stimulant market.
- Eli Lilly: Major incumbent pharma with deep CNS/Alzheimer's R&D pipeline and established CNS commercial infrastructure. Relevant peer for the Alzheimer's pipeline opportunity and competitive context.
Direct peers
- Adamas Pharmaceuticals: CNS specialty pharma with neurology products including Parkinson's and dyskinesia treatments. Comparable as a focused CNS specialty commercial-stage company with similar scale and pipeline strategy.
- Supernus Pharmaceuticals: Specialty CNS pharmaceutical company marketing ADHD and neurology products (e.g., Qelbree). Closely comparable to Corium as a CNS-focused specialty pharma with a similar ADHD commercial franchise and CNS pipeline.
- Neos Therapeutics: Specialty pharma focused on ADHD and CNS disorders with extended-release and orally disintegrating formulations. Comparable as an ADHD-focused specialty CNS pharma with formulation-driven differentiation.
- Ironshore Therapeutics: Specialty CNS pharma commercializing ADHD treatments (e.g., Jornay PM). Comparable as a smaller CNS specialty competitor targeting the same ADHD prescriber base as AZSTARYS.
- KemPharm: CNS specialty pharma whose prodrug technology underpins AZSTARYS (licensed to Corium for commercialization). Highly comparable product-technology overlap and ADHD focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Corium International social profiles
Digital presenceCorium International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corium International leadership team
Management profileNumber of profiles
Profiles3 records
Corium International funding detail
Funding detailFunding overview
Funding rounds6 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corium International M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corium International
What does Corium International do?
Corium International is a pharmaceutical company that develops and commercializes advanced transdermal drug delivery technologies and CNS (central nervous system) therapies. Its primary commercial product is AZSTARYS, an FDA-approved medication for ADHD, while it also advances a development pipeline including an Alzheimer's disease treatment.
Is Corium International a public or private company?
Corium International is a public company. It is classified as public and is currently operating.
When was Corium International founded?
Corium International was founded in 1995. It employs 501 to 1,000 people.
Where is Corium International based?
Corium International is headquartered in Menlo Park, United States, in the North America region.
How does Corium International make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Corium International's main competitors?
Broad incumbents on record are Biogen, Jazz Pharmaceuticals, Pfizer, Teva Pharmaceutical Industries and Eli Lilly. Direct peers are Adamas Pharmaceuticals, Supernus Pharmaceuticals, Neos Therapeutics, Ironshore Therapeutics and KemPharm.
Does Corium International have an API?
No public API is recorded for Corium International.